Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record.

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort

Open access
Ma, C., Fedorak, R. N., Kaplan, G. G., Dieleman, L. A., Devlin, S. M., Stern, N., Kroeker, K. I., Seow, C. H., Leung, Y., Novak, K. L., Halloran, B. P., Huang, V. W., Wong, K., Blustein, P. K., Ghosh, S., Panaccione, R. · 2017 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Ustekinumab is a monoclonal antibody targeting interleukins‐12 and ‐23, with efficacy in Crohn's disease ( CD ) demonstrated in clinical trials. Aim: To assess the real‐world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically‐refractory CD . Methods: A retrospective multicentre cohort study was performed on CD patients receiving ustekinumab between 2011 and 2016. The primary outcome was achievement of clinical and objective steroid‐free response and remission at 3, 6 and 12 months. Clinical response and remission were defined by reduction in Harvey Bradshaw Index ( HBI ) of ≥3 points and an HBI ≤4 points respectively. Objective response was defined by improvement in endoscopic or radiographic CD , as assessed by ileocolonoscopy, contrast‐enhanced ultrasound or CT / MR enterography. Objective remission was defined by endoscopic mucosal healing or complete resolution of inflammatory parameters on radiographic assessment. Results: A total of 167 CD patients were treated with ustekinumab. 95.2% (159/167) previously failed anti‐ TNF therapy. Median follow‐up was 45.6 weeks ( IQR : 24.4–88.9). At 3 months, clinical response was achieved in 38.9% (65/167) and remission in 15.0% (25/167) of patients. At 6 months, clinical response was achieved in 60.3% (91/151) and remission in 25.2% (38/151) of patients. At 12 months, clinical response was achieved in 59.5% (66/111) and remission in 27.9% (31/111) of patients. Endoscopic or radiographic response was demonstrated in 54.5% (67/123) at 6 months and 55.8% (48/86) of patients at 12 months. Conclusions: Ustekinumab is an effective therapeutic option for inducing and maintaining clinical, endoscopic and radiographic response in patients with Crohn's disease failing anti‐ TNF therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.14016

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Ma, C., Fedorak, R. N., Kaplan, G. G., Dieleman, L. A., Devlin, S. M., Stern, N., Kroeker, K. I., Seow, C. H., Leung, Y., Novak, K. L., Halloran, B. P., Huang, V. W., Wong, K., Blustein, P. K., Ghosh, S., & Panaccione, R.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2017-03-02
Volume
45
Issue
9
Pages
1232-1243
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2593531649
Cited by
185
References
0
FWCI
13.58
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.